Compare Nebius Group NV (NBIS) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nebius Group NV vs Viatris Inc — how do they compare? Nebius Group NV trades at $233.07 (market cap $65.34B), while Viatris Inc trades at $16.5 (market cap $18.95B). The key difference: Nebius Group NV is far larger — about 3.4× Viatris Inc's market cap, and Viatris Inc pays a 2.91% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| NBIS | VTRS | |
|---|---|---|
Market Cap | $65.34B | $18.95B |
Sector | Technology | Health |
52-Week High | $286.69 | $17.86 |
52-Week Low | $73.87 | $9.49 |
Enterprise Value | $67.47B | $31.07B |
Dividend Yield | — | 2.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NBIS stock trades at $243.88, up 7.73% on the day, driven by a strategic partnership with Palantir for sovereign AI infrastructure, as reported by Benzinga on September 8, 2026. The stock shows bullish technical signals with strong moving average support and a consensus analyst price target of $300.43. Revenue growth is projected to surge from $530 million in 2025 to $1.4 billion in 2026, though net income margins are thin at 3.13%.
The outlook is positive due to high AI demand and analyst optimism, with 80% buy ratings. Risks include elevated valuation multiples, such as a P/E of 74.61, and execution challenges in scaling infrastructure. Investors should weigh growth potential against profitability concerns and market volatility.
Viatris (VTRS) trades at $16.61, down 1.6% on the day, with a bullish technical signal but mixed moving averages. The company reported Q2 2026 EPS of $0.69, beating estimates, and revenue growth of 5% year-over-year. Despite negative net income margins, strong cash flow generation supports dividends and buybacks. Recent news highlights pipeline progress and a higher 2026 outlook.
Outlook: Viatris shows operational strength with consistent earnings beats and cash flow, but high P/E and negative profitability pose risks. Investment opportunity lies in deleveraging and pipeline advancements, while headwinds include generic drug pricing pressure and regulatory uncertainty. Analyst sentiment is mixed with a hold-heavy consensus.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
